The best low-cost GLP-1 program is not the one with the lowest price its the one that delivers safe, consistent, medically supervised care at a price you can afford
In this weeks blog, our Founder and Medical Director, Mr Guy Slater, addresses growing public concern about a potential link between GLP-1 medications and pancreatitis
This is where the mass-market volume will likely settle once price competition has done its work
it reflects the current consensus in peer-reviewed obesity medicine literature and the clinical guideline positions of major endocrinology and bariatric medicine professional societies
Its not only causing me stress, but it is making me angry. Starting Tuesday, CVS Caremark a major pharmacy benefit manager that serves as a middleman for health insurers, large employers and other payers to manage their prescription drug plans will stop covering Eli Lillys Zepbound, a blockbuster GLP-1 drug that has been approved by the US Food and Drug Administration since November 2023 for chronic weight management in adults with obesity or who are overweight
